Results 11 to 20 of about 1,845 (139)
STATINS AND RISK OF INFECTIOUS DISEASES
Рациональная фармакотерапия в кардиологии, 2015 Besides hypolipidemic effect statins demonstrate some not-lipid (pleotropic) ones. Special attention has been paying to statin inducing reduction in bacterial infections incidence and severity, and pneumonia particularly.
O. M. Drapkina, R. N. Shepel'
doaj +1 more source
Thin layer chromatography of some statins in aqueous organic mobile phases modified with buff er solutions [PDF]
Известия Саратовского университета. Новая серия: Серия Химия. Биология. Экология, 2023 The influence of a number of factors on the chromatographic properties of statins (atorvastatin, rosuvastatin, simvastatin) in normal-phase and reverse-phase chromatography modes has been studied by the method of the thin-layer chromatography (TLC) in ...
Sumina, Elena G. +2 more
doaj +1 more source
Механизмы нефропротекторных свойств статинов при гентамициновой острой почечной недостаточности [PDF]
, 2016 ПОЧЕЧНАЯ НЕДОСТАТОЧНОСТЬ ОСТРАЯСТАТИНЫАТОРВАСТАТИНЛОВАСТАТИНСИМВАСТАТИННЕФРОПРОТЕКЦИЯЭКСПЕРИМЕНТЫ НА ...
Заморский, И. И. +3 more
core +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Statins, the most common drugs for reduction in lipid levels, are “strategic” medicinal products for the treatment and prevention of cardiovascular diseases caused by atherosclerosis. The milestones of lipid-lowering therapy history are presented as well
L. N. Malay
doaj +1 more source
STATINS AND URSODEOXYCHOLIC ACID: COOPERATION OR NEUTRALITY?
Рациональная фармакотерапия в кардиологии, 2016 Results of combined therapy of gallstone disease (GSD), non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH) and hypercholesterolemia (HCE) with statins and ursodeoxycholic acid (UDCA) are analyzed.
I. N. Grigorieva, Y. M. Pozdnyakov
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Widespread use of antihypertensive and lipid-lowering agents in clinical practice determines the necessity of knowledge of their pleiotropic effects.
I. A. Skripnikova +3 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To evaluate the frequency of prescription, efficacy and patients adherence to statin therapy in a cohort of patients with ischemic heart disease (IHD), confirmed by coronary angiography data, during the period from 2004 to 2010 based on the data ...
S. N. Tolpygina +2 more
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To assess the quality of drug therapy and its correspondence with current clinical guidelines in patients with proven stable ischemic heart disease (IHD) before admission, during inpatient stay in hospital and after hospital discharge.Material and ...
S. N. Tolpygina +2 more
doaj +1 more source
THE SAFETY OF STATINS: WHAT A PHYSICIAN NEEDS TO KNOW
Рациональная фармакотерапия в кардиологии, 2015 Various aspects of the safety of statins in clinical practice are discussed: hepatotoxicity, myopathy and rhabdomyolysis, the impact on the diabetes and cognitive dysfunction onset, renal function impairment.
D. A. Napalkov
doaj +1 more source
Рациональная фармакотерапия в кардиологии, 2015 Aim. To assess the quality of lipid-lowering therapy in high risk patients with cardiovascular diseases during medical supervision in specialized center.Material and methods. The data of the PROFIL register are used.
S. Yu. Martsevich +4 more
doaj +1 more source